Genetic Study in Pheochromocytoma: Is It Possible to Stratify the Risk of Hereditary Pheochromocytoma?

Genetic testing Hereditary syndrome Multiple endocrine neoplasia type 2 Pheochromocytoma Sporadic pheochromocytoma

Journal

Neuroendocrinology
ISSN: 1423-0194
Titre abrégé: Neuroendocrinology
Pays: Switzerland
ID NLM: 0035665

Informations de publication

Date de publication:
2023
Historique:
received: 05 08 2022
accepted: 17 01 2023
medline: 5 6 2023
pubmed: 25 1 2023
entrez: 24 1 2023
Statut: ppublish

Résumé

It is estimated that 30-40% of patients with apparently sporadic pheochromocytomas (PHEOs) have an inherited predisposition syndrome. The aim of our study was to develop a predictive model of hereditary PHEO based on the clinical, hormonal, and radiological features present at the diagnosis of patients with PHEOs. A retrospective multicenter cohort study of patients with PHEOs with available genetic study from 18 tertiary hospitals. Clinical, biochemical, and radiological features were used to build a multivariate logistic regression model. The estimation of all possible equations was used to select the model with the best diagnostic accuracy (lower Akaike index). A total of 245 patients were included: 169 (69.0%) patients with sporadic PHEOs and 76 (31%) with hereditary PHEOs. The parsimonious predictive model with the highest diagnostic accuracy for the prediction of hereditary PHEO combined the variables age, non-cardiovascular disease, urinary norepinephrine levels, and tumor size. The area under the ROC curve of this model was 0.800 (0.705-0.887). Based on the predictive model, the probability of hereditary PHEO in patients older than 60 years with cardiovascular disease, high levels of urinary norepinephrine and unilateral PHEOs >60 mm was <2%. And if the age was above 80 years, lower than 1%. The probability of sporadic PHEO linearly increased with age (MH Test for linear Trend: χ2 (1) = 30.05; p < 0.001). In certain populations such as old patients with cardiovascular disease, with high levels of urinary norepinephrine and large tumors in which the probability of hereditary PHEO is very low, genetic testing could be avoided in the absence of specific suspicion.

Identifiants

pubmed: 36693324
pii: 000529319
doi: 10.1159/000529319
doi:

Substances chimiques

Norepinephrine X4W3ENH1CV

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-666

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Marta Araujo-Castro (M)

Endocrinology and Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Instituto de Investigación Biomédica Ramón y Cajal (IRYCIS), Madrid, Spain.
Medicine Department, University of Alcalá, Madrid, Spain.

César Mínguez Ojeda (C)

Urology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Iñigo García Sanz (I)

General and Digestive Surgery Department, Hospital Universitario de La Princesa, Madrid, Spain.

Maria Calatayud (M)

Endocrinology and Nutrition Department, Hospital Universitario Doce de Octubre, Madrid, Spain.

Felicia Hanzu (F)

Endocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain.

Mireia Mora (M)

Endocrinology and Nutrition Department, Hospital Clinic, Barcelona, Spain.

Almudena Vicente (A)

Endocrinology and Nutrition Department, Hospital Universitario de Toledo, Toledo, Spain.

Concepción Blanco Carrera (C)

Endocrinology and Nutrition Department, Hospital Universitario Príncipe de Asturias, Madrid, Spain.

Paz de Miguel Novoa (P)

Endocrinology and Nutrition Department, Hospital Clínico San Carlos, Madrid, Spain.

María Del Carmen López García (MDC)

Endocrinology and Nutrition Department, Hospital Universitario de Albacete, Albacete, Spain.

Cristina Lamas (C)

Endocrinology and Nutrition Department, Hospital Universitario de Albacete, Albacete, Spain.

Laura Manjón-Miguélez (L)

Endocrinology and Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain.
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.

María Del Castillo Tous (M)

Endocrinology and Nutrition Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain.

Pablo Rodríguez de Vera (P)

Endocrinology and Nutrition Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain.

Rebeca Barahona San Millán (R)

Endocrinology and Nutrition Department, Institut Català de la Salut Girona, Girona, Spain.

Mónica Recasens (M)

Endocrinology and Nutrition Department, Institut Català de la Salut Girona, Girona, Spain.

Mariana Tomé Fernández-Ladreda (M)

Endocrinology and Nutrition Department, Hospital Universitario de Puerto Real, Cádiz, Spain.

Nuria Valdés (N)

Endocrinology and Nutrition Department, Hospital Universitario de Cabueñes, Asturias, Spain.

Paola Gracia Gimeno (P)

Endocrinology and Nutrition Department, Hospital Royo Villanueva, Zaragoza, Spain.

Cristina Robles Lazaro (C)

Endocrinology and Nutrition Department, Hospital Universitario de Salamanca, Salamanca, Spain.

Theodora Michalopoulou (T)

Department of Endocrinology and Nutrition, Joan XXIII University Hospital, Tarragona, Spain.

Paola Parra Ramírez (P)

Endocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain.

Mónica Marazuela (M)

Endocrinology and Nutrition Department, Hospital Universitario La Princesa, Madrid, Spain.

Cristina Álvarez Escolá (C)

Endocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain.

Rogelio García Centeno (R)

Endocrinology and Nutrition Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH